文献速递神经免疫认知障碍与痴呆

N-乙酰葡糖胺标志物与进展型多发性硬化及神经变性的关联

Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration.
PubMed 文献 · JAMA Neurol · 2021-01-01

该横断面发现与验证研究在美国和德国两个学术多发性硬化中心开展,发现队列纳入54例多发性硬化患者和66例健康对照,验证队列纳入180例患者,采用靶向串联质谱检测血清N-乙酰己糖胺(HexNAc)水平。结果显示进展型多发性硬化患者血清HexNAc显著低于健康对照和复发缓解型患者,且低HexNAc水平与更差EDSS评分、更低丘脑体积、更薄视网膜神经纤维层及18个月时更大比例脑体积丢失相关。

要点

  • 进展型多发性硬化患者血清HexNAc水平显著低于健康对照和复发缓解型患者。
  • 低HexNAc水平与更差EDSS评分、更低丘脑体积和更薄视网膜神经纤维层相关。
  • 低基线HexNAc水平与18个月时更大比例脑体积丢失相关。

核心结论

  • GlcNAc及其立体异构体(HexNAc)缺乏可能是进展型多发性硬化的生物标志物。
  • GlcNAc缺乏可能与多发性硬化患者的进展型疾病和神经变性相关。

研究设计与样本

  • 横断面发现研究在美国和德国2个学术多发性硬化中心开展,发现队列招募54例多发性硬化患者和66例健康对照,招募时间为2010年4月20日至2013年6月21日。
  • 横断面验证研究在学术多发性硬化研究中心的筛查访视中招募180例多发性硬化患者,招募时间为2007年4月9日至2016年2月29日。
  • 血清样本分析时间为2013年12月2日至2015年3月2日,统计分析时间为2020年2月23日至2021年3月18日。
  • 采用靶向串联质谱评估血清GlcNAc及其立体异构体(HexNAc)水平,验证研究的次要结局包括影像学和临床疾病标志物。

主要发现

  • 发现队列中,健康对照血清HexNAc平均(SD)水平为710(174)nM,复发缓解型多发性硬化患者为682(173)nM(P = .04),进展型患者为548(101)nM,显著低于健康对照(P = 9.55 × 10-9)和复发缓解型患者(P = 1.83 × 10-4)。
  • 验证队列中,复发缓解型患者血清HexNAc平均(SD)水平为709(193)nM,进展型患者为405(161)nM,两组差异显著(P = 7.6 × 10-18)。
  • 较低血清HexNAc水平与更差EDSS评分相关(ρ = -0.485;P = 4.73 × 10-12),与更低丘脑体积相关(t = 1.7;P = .04),与更薄视网膜神经纤维层相关(B = 0.012 [SE = 7.5 × 10-11];P = .008)。
  • 低基线血清HexNAc水平与18个月时更大比例脑体积丢失相关(t = 1.8;P = .04)。

临床怎么用

  • 血清HexNAc水平可作为进展型多发性硬化的潜在生物标志物,辅助识别进展型疾病和神经变性风险较高的患者。
  • 低HexNAc水平与更差EDSS评分、更低丘脑体积、更薄视网膜神经纤维层及更大脑体积丢失相关,提示可用于疾病进展监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: N-glycan branching modulates cell surface receptor availability, and its deficiency in mice promotes inflammatory demyelination, reduced myelination, and neurodegeneration. N-acetylglucosamine (GlcNAc) is a rate-limiting substrate for N-glycan branching, but, to our knowledge, endogenous serum levels in patients with multiple sclerosis (MS) are unknown. OBJECTIVE: To investigate a marker of endogenous serum GlcNAc levels in patients with MS. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional discovery study and cross-sectional confirmatory study were conducted at 2 academic MS centers in the US and Germany. The discovery study recruited 54 patients with MS from an outpatient clinic as well as 66 healthy controls between April 20, 2010, and June 21, 2013. The confirmatory study recruited 180 patients with MS from screening visits at an academic MS study center between April 9, 2007, and February 29, 2016. Serum samples were analyzed from December 2, 2013, to March 2, 2015. Statistical analysis was performed from February 23, 2020, to March 18, 2021. MAIN OUTCOMES AND MEASURES: Serum levels of GlcNAc plus its stereoisomers, termed N-acetylhexosamine (HexNAc), were assessed using targeted tandem mass spectroscopy. Secondary outcomes (confirmatory study) comprised imaging and clinical disease markers. RESULTS: The discovery cohort included 66 healthy controls (38 women; mean [SD] age, 42 [20] years), 33 patients with relapsing-remitting MS (RRMS; 25 women; mean [SD] age, 50 [11] years), and 21 patients with progressive MS (PMS; 14 women; mean [SD] age, 55 [7] years). The confirmatory cohort included 125 patients with RRMS (83 women; mean [SD] age, 40 [9] years) and 55 patients with PMS (22 women; mean [SD] age, 49 [80] years). In the discovery cohort, the mean (SD) serum level of GlcNAc plus its stereoisomers (HexNAc) was 710 (174) nM in healthy controls and marginally reduced in patients with RRMS (mean [SD] level, 682 [173] nM; P = .04), whereas patients with PMS displayed markedly reduced levels compared with healthy controls (mean [SD] level, 548 [101] nM; P = 9.55 × 10-9) and patients with RRMS (P = 1.83 × 10-4). The difference between patients with RRMS (mean [SD] level, 709 [193] nM) and those with PMS (mean [SD] level, 405 [161] nM; P = 7.6 × 10-18) was confirmed in the independent confirmatory cohort. Lower HexNAc serum levels correlated with worse expanded disability status scale scores (ρ = -0.485; P = 4.73 × 10-12), lower thalamic volume (t = 1.7; P = .04), and thinner retinal nerve fiber layer (B = 0.012 [SE = 7.5 × 10-11]; P = .008). Low baseline serum HexNAc levels correlated with a greater percentage of brain volume loss at 18 months (t = 1.8; P = .04). CONCLUSIONS AND RELEVANCE: This study suggests that deficiency of GlcNAc plus its stereoisomers (HexNAc) may be a biomarker for PMS. Previous preclinical, human genetic, and ex vivo human mechanistic studies revealed that N-glycan branching and/or GlcNAc may reduce proinflammatory responses, promote myelin repair, and decrease neurodegeneration. Combined, the data suggest that GlcNAc deficiency may be associated with progressive disease and neurodegeneration in patients with MS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Brandt AU, Sy M, Bellmann-Strobl J, et al. Association of a Marker of N-Acetylglucosamine With Progressive Multiple Sclerosis and Neurodegeneration. JAMA Neurol. 2021. PMID: 33970182. doi:10.1001/jamaneurol.2021.1116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。